Literature DB >> 31919773

Aflibercept plus micropulse laser versus aflibercept monotherapy for diabetic macular edema: 1-year results of a randomized clinical trial.

Mahmoud Alaa Abouhussein1, Amir Ramadan Gomaa2.   

Abstract

PURPOSE: To evaluate the role of adjuvant micropulse laser with aflibercept injections in the management of treatment naive center involving DME, looking at decreased treatment burden and increased efficacy as outcomes after 1 year.
METHODS: This was a prospective, single center, randomized trial that included 40 eyes (40 patients) with previously untreated center involved DME. Patients were randomly assigned to receive either aflibercept plus micropulse laser (group A) or aflibercept monotherapy (group B).
RESULTS: Overall, 40 patients were included in the study; they were randomized into either group A (aflibercept + micropulse; 20 patients) or group B (aflibercept monotherapy; 20 patients). The mean number of injections after the loading dose was 4.5 ± 1.4 in group A and was 5.4 ± 1.7 in group B, and the difference between both groups was statistically significant (P = 0.029).
CONCLUSION: Adding 577-nm micropulse laser to aflibercept is effective for treatment naïve DME and is associated with decreased number of injections.

Entities:  

Keywords:  Afibercept; Diabetic macular edema; Micropulse laser

Year:  2020        PMID: 31919773     DOI: 10.1007/s10792-019-01280-9

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  6 in total

1.  Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema.

Authors:  Tomoaki Tatsumi; Yoko Takatsuna; Toshiyuki Oshitari; Tomomi Kaiho; Yohei Kawasaki; Yuki Shiko; Takeshi Sugawara; Takayuki Baba; Shuichi Yamamoto
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

Review 2.  Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options.

Authors:  Josh O Wallsh; Ron P Gallemore
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

Review 3.  Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options.

Authors:  Daniele Veritti; Valentina Sarao; Valentina Soppelsa; Paolo Lanzetta
Journal:  Clin Ophthalmol       Date:  2021-01-29

4.  Subthreshold micropulse laser adjuvant to bevacizumab versus bevacizumab monotherapy in treating diabetic macular edema: one- year- follow-up.

Authors:  Leila El Matri; Ahmed Chebil; Khaled El Matri; Yousra Falfoul; Zouheir Chebbi
Journal:  Ther Adv Ophthalmol       Date:  2021-09-02

Review 5.  Efficacy and Safety of Aflibercept Therapy for Diabetic Macular Edema: A Systematic Review and Meta-Analysis.

Authors:  Sangeetha Santhakumaran; Ali Salimi; Vanessa C Brunetti; John Galic
Journal:  J Curr Ophthalmol       Date:  2022-07-26

6.  Intravitreal Dexamethasone Implant (IDI) Alone and Combined with Navigated 577 nm Subthreshold Micropulse Laser (SML) for Diabetic Macular Oedema.

Authors:  Lisa Toto; Rossella D'Aloisio; Alberto Quarta; Daniele Libertini; Giada D'Onofrio; Chiara De Nicola; Anna Romano; Rodolfo Mastropasqua
Journal:  J Clin Med       Date:  2022-09-02       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.